*WHO HAS MISLED THE PUBLIC, LIED AND CONCEALED THE FINANCIAL STAKE OF GSK IN AN EBOLA EMERGENCY DECLARATION
*WHO SPOKESPERSON GREGORY HARTL DENIED ANY EBOLA VACCINE WAS AVAILABLE IN AN EMAIL IN APRIL
*YET IN MARCH GSK APPROACHED WHO WITH ITS EBOLA VACCINE CANDIDATE
*AS SOON AS WHO DECLARED EBOLA AN INTERNATIONAL EMERGENCY IN AUGUST, GSK WAS GIVEN THE GREEN LIGHT TO PRODUCE THE EBOLA VACCINE
*LUCRATIVE CONTRACT WHICH COULD INVOLVE 230,000 DOSES IN APRIL ALREADY
*RERUN OF SWINE FLU SCANDAL OF 2009 WHEN WHO CONCEALED CONFLICTS OF INTERESTS FROM PUBLIC IN SWINE FLU EMERGENCY DECLARATION
*SCIENTISTS WITH LINKS TO GSK AND BIG PHARMA ADVISED WHO TO DECLARE SWINE FLU AN EMERGENCY, GENERATING WINDFALL
In May 2013 GlaxoSmithKline (GSK) bought a Swiss vaccine-maker for $325m, called Okairos, which had a preclinical Ebola vaccine candidate.
In March 2014, GSK contacted the World Health Organisation (WHO) to let it know that it had an Ebola vaccine.
That means, as early as March, WHO knew that GSK had a financial stake in WHO declaring Ebola declaration of emergency of international concern because such a declaration would trigger lucrative vaccine contracts for GSK.
Yet in an email sent to me on April 3, WHO spokesperson Gregory Haertl denied any conflict of interest, writing:
“And I am not sure I understand your question about Conflicts of Interest: how can there be, when there is no vaccine and no antivirals available for Ebola, and the treatments that are being trialled are from already-existing drugs?”
In fact, as soon as WHO declared Ebola an international emergency in August, GSK was given the green light to produce its Ebola vaccine.
My original query about a conflict of interest was sent to Glenn Thomas, the WHO spokesperson who died in a mysterious MH17 plane crash in the Ukraine, which still has not been explained.
Why is this important? The only finding of a major swine flu vaccine inquiry in 2010 was that WHO had concealed the ties of its experts to Big Pharma.
Many of the scientists on the WHO’s emergency panel had links with firms including GlaxoSmithKline, who made millions manufacturing swine flu vaccines as soon as WHO declared the swine flu an emergency.
Read more: http://www.dailymail.co.uk/health/article-1302505/WHO-swine-flu-advisers-ties-drug-firms-Experts-linked-vaccine-producers.html#ixzz3ITIixbbd
Follow us: @MailOnline on Twitter | DailyMail on Facebook
In 2014, WHO has once more concealed conflicts of interests from the public. The email of Gregory Hartl is proof that WHO has deliberately misled the public about the financial stake which GSK had in inflating Ebola deaths and in WHO declaring Ebola an international emergency.
According to a Discussion Note, WHO URGENT Ebola Virus Disease (EVD) vaccine access meeting October 21, 2014. Norwegian Institute of Public Health, Oslo, Norway, GSK could scale up production to 230,000 doses by April already.
“GSK estimates (see table below, and here) that it will have 24,000 doses of its vaccine
ready by January for the efficacy trials. If it cranks up production to full capacity before
the those trials are complete, the company could have 230,000 doses available in April.